| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Fmr. Chief Commercial Officer | Chief Commercial Officer +1 more
2 companies
John Nosenzo last filed a Form 4 in June 2023, as Fmr. Chief Commercial Officer at BVS. The filings on record cover 2 companies. John Nosenzo's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns John Nosenzo a strong insider score of 84/100, based on 5 past trades. Over a 12-month horizon, all 5 of those trades were profitable, with an average 12-month return of +77.3%.
At the last filing, the largest reported position was 87,148 shares of BVS. The BVS filings lean toward selling, a net 66,139 shares.
John Nosenzo has 9 Form 4 filings on record from February 2021 to June 2023, across 2 companies: Director at TELA Bio (TELA), 2021–2023; Fmr. Chief Commercial Officer at Bioventus (BVS), 2021–2022.
The 17 reported transactions were 5 option or other derivative awards, 5 open-market sales, 3 option exercises and 2 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $7K and 3 sales worth about $741K.
The only open-market purchase was 500 shares of BVS at an average $13.00 on February 11, 2021, about $7K.
The largest open-market sale was 65,963 shares of BVS at an average $11.12 on April 4, 2022, about $734K. Twelve months later BVS was down 92%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 3, 2022 | BVS Bioventus Inc. | Fmr. Chief Commercial Officer | Sell10b5-1 | 142 | $8.81 | $1,251.15 | -0.2% | -62.7% | -57.4% | |
| Apr 4, 2022 | BVS Bioventus Inc. | Chief Commercial Officer | Sale+OE | 65,963 | $11.12 | $733,501.96 | -44.0% | -43.9% | -91.7% | |
| Feb 14, 2022 | BVS Bioventus Inc. | Chief Commercial Officer | Sale+OE | 534 | $11.99 | $6,401.33 | -1.2% | -29.9% | -85.6% | |
| Feb 11, 2021 | BVS Bioventus Inc. | Chief Commercial Officer | Buy | 500 | $13.00 | $6,500.00 | New | - | - |